

Karina Dahl Steffensen
Klinisk lektor
Onkologisk Afdeling
Center Lillebælt
E-mail: karina.dahl.steffensen@rsyd.dk
Telefon: 21770727



Ansættelse

Klinisk professor

IRS, Sygehus Lillebælt, Onkologi
Syddansk Universitet
1. sep. 2014 → 31. mar. 2023

Klinisk professor

IRS, Sygehus Lillebælt, Center for fælles beslutningstagning
Syddansk Universitet
1. feb. 2018 → 31. mar. 2023

Leder - Center for Fælles Beslutningstagning

1. nov. 2014 → present

Overlæge - klinisk onkologi

Vejle Sygehus
Vejle, Danmark
1. okt. 2014 → present

Publikationer - peer reviewed

A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid

Søndergaard, S. R., Madsen, P. H., Hilberg, O., Jensen, K. M., Olling, K. & Steffensen, K. D., nov. 2019, I : Patient Education and Counseling. 102, 11, s. 1961-1968

Shared decision making when patients consider surgery for lumbar herniated disc: development and test of a patient decision aid

Andersen, S. B., Andersen, M. Ø., Carreon, L. Y., Coulter, A. & Steffensen, K. D., 4. okt. 2019, I : BMC Medical Informatics and Decision Making. 19, 9 s., 190.

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer

Hansen, T. F., Nederby, L., Zedan, A. H., Mejlholm, I., Henriksen, J. R., Dahl Steffensen, K., Thomsen, C. B., Raunkilde, L., Jensen, L. H. & Jakobsen, A., jul. 2019, I : Translational Oncology. 12, 7, s. 968-972

Development of a patient decision aid template for use in different clinical settings

Olling, K., Bechmann, T., Madsen, P. H., Hugger Jakobsen, E., Toftdahl, D. B., Hilberg, O., Coulter, A. & Dahl Steffensen, K., jun. 2019, I : European Journal for Person Centered Healthcare . 7, 1

The impact of a patient decision aid on shared decision making behaviour in oncology care and pulmonary medicine - A field study based on real-life observations.

Olling, K., Stie, M., Winther, B. & Dahl Steffensen, K., 29. maj 2019, I : Journal of Evaluation in Clinical Practice Online.

Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy

Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Van Calster, B., Stankusova, H., Delle Marchette, M., Mephon, A., Rouzier, R., Witteveen, P. O., Vergani, P., Van Calsteren, K., Rob, L. & Amant, F., 7. maj 2019, I :

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 29, 4, s. 676-682

Delta tocotrienol in recurrent ovarian cancer. A phase II trial

Thomsen, C. B., Andersen, R. F., Steffensen, K. D., Adimi, P. & Jakobsen, A., mar. 2019, I : Pharmacological Research. 141, s. 392-396

Factors Affecting Patient Decision-making on Surgery for Lumbar Disc Herniation

Andersen, S. B., Birkelund, R., Andersen, M. Ø., Carreon, L. Y., Coulter, A. & Steffensen, K. D., 15. jan. 2019, I : Spine. 44, 2, s. 143-149

The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer

Hjortkjær, M., Malik Aagaard Jørgensen, M., Waldstrøm, M., Ørnskov, D., Søgaard-Andersen, E., Jakobsen, A. & Dahl-Steffensen, K., jan. 2019, I : International Journal of Gynecological Cancer. 29, 1, s. 166-173

Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy

Boucek, J., de Haan, J., Halaska, M. J., Plzak, J., Van Calsteren, K., de Groot, C. J. M., Dahl Steffensen, K., Fruscio, R., Massolt, E. T., Klaritsch, P., Zola, P., Amant, F. & International Network on Cancer, Infertility, and Pregnancy, jun. 2018, I : The Laryngoscope. 128, 6, s. 1493-1500

Behandling af primær og recidiverende ovariecancer

Rosendahl, M., Mosgaard, B. J. & Steffensen, K. D., 22. jan. 2018, I : Ugeskrift for Laeger. 180, 4, s. 2-6 V03170213.

Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status

Hjortkjær, M., Kanstrup, H., Jakobsen, A. & Dahl Steffensen, K., 1. jan. 2018, I : Cancer Treatment and Research Communications. 14, s. 7-12

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy

International Network on Cancer, Infertility and Pregnancy, 2018, I : Breast Cancer Research and Treatment. 168, 2, s. 551-557

Experiences of involvement in decision-making for patients with breast cancer: A phenomenological-hermeneutical study

Christoffersen, N., Olling, K., Dahl Steffensen, K. & Birkelund, R., 2018, I : European Journal for Person Centered Healthcare . 6, 2, s. 237-247

How participatory action research changed our view of the challenges of shared decision-making training

Ammentorp, J., Wolderslund, M., Timmermann, C., Larsen, H., Dahl Steffensen, K., Nielsen, A., Lau, M., Winther, B., Jensen, L. H., Assing Hvidt, E., Hvidt, N. C. & Gulbrandsen, P., 2018, I : Patient Education and Counseling. 101, 4, s. 639-646

Lessons in Integrating Shared Decision-Making Into Cancer Care

Steffensen, K. D., Vinter, M., Crüger, D., Dankl, K., Coulter, A., Stuart, B. & Berry, L. L., 2018, I : Journal of Oncology Practice. 14, 4, s. 229-235

Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients

de Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Mhallem Gziri, M., Halaska, M. J., Fruscio, R., Lok, C. A. R., Boere, I. A., Zola, P., Ottevanger, P. B., de Groot, C. J. M., Peccatori, F. A., Dahl Steffensen, K., Cardonick, E. H., Polushkina, E., Rob, L., Ceppi, L., Sukhikh, G. T. & 3 flere, Han, S. N., Amant, F. & International Network on Cancer and Infertility Pregnancy (INCIP), 2018, I : Lancet Oncology. 19, 3, s. 337-346

Implementing shared decision making in Denmark: First steps and future focus areas

Dahl Steffensen, K., Hjelholt Baker, V. & Vinter, M. M., jun. 2017, I : Zeitschrift fuer Evidenz, Fortbildung und Qualitaet im Gesundheitswesen. 123-124, s. 36-40

Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma

de Haan, J., Lok, C. A., de Groot, C. J. M., Crijns, M. B., Van Calsteren, K., Dahl Steffensen, K., Halaska, M. J., Altintas, S., Boere, I. A., Fruscio, R., Kolawa, W., Witteveen, P. O., Amant, F. & International Network on Cancer, Infertility and Pregnancy (INCIP), jun. 2017, I : Melanoma Research. 27, 3, s. 218-223

Clopidogrel paclitaxel drug-drug interaction: A pharmacoepidemiologic study

Agergaard, K., Mau-Sørensen, M., Stage, T. B., Jørgensen, T. L., Hassel, R. E., Dahl Steffensen, K., Pedersen, J. W., Milo, M. L. H., Poulsen, S. H., Pottegård, A., Hallas, J., Brøsen, K. & Bergmann, T. K., 2017, I : Clinical Pharmacology and Therapeutics. 102, Renal Therapy, s. 547-553

Ovariecancer: tidlig opsporing i almen praksis og behandling

Jensen, P. T. & Dahl Steffensen, K., 2017, I : Best Practice - Almen praksis.

The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection

Hjortkjær, M., Waldstrøm, M., Jakobsen, A., Kanstrup, H., Søgaard-Andersen, E. & Dahl Steffensen, K., 2017, I : International Journal of Gynecological Pathology. 36, 2, s. 180-189

Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

Steffensen, K. D., Adimi, P. & Jakobsen, A., 2017, I : International Journal of Gynecological Cancer. 27, 9, s. 1842-1849

The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Boisen, M. K., Madsen, C. V., Dehlendorff, C., Jakobsen, A., Johansen, J. S. & Dahl Steffensen, K., okt. 2016, I : International Journal of Gynecological Cancer. 26, 8, s. 1390-8

A case report of long term bevacizumab treatment in multiresistant ovarian cancer

Kargo, A. S., Adimi, P. & Dahl-Steffensen, K., 19. jun. 2016, I : International Journal of Cancer Therapy and Oncology. 4, 2, 4 s., 4214.

Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue: A new paradigm in genetic counseling

Petersen, A. H., Jørgensen, M. M. A., Nielsen, H. R., Dahl Steffensen, K., Waldstrøm, M. & Bojesen, A., 6. jan. 2016, I : European Journal of Human Genetics. 24, 8, s. 1104-1111

Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Lund, B., Sørensen, S. M., Petzold, M. & Jakobsen, A., 2016, I : Oncology Letters. 11, 6, s. 3967-3974

Cancer under graviditeten

Pedersen, B. W., Storgaard, L., Clausen, M. B., Kroman, N., Langhoff-Roos, J. & Steffensen, K. D., 29. jun. 2015, I : Ugeskrift for Laeger. 177, 27, 5 s., V12140714.

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab

Steffensen, K. D., Madsen, C. V., Andersen, R. F., Waldstrøm, M., Adimi, P. & Jakobsen, A., okt. 2014, I : European Journal of Cancer. 50, 15, s. 2611-8 8 s.

Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature

Verheecke, M., Halaska, M. J., Lok, C. A., Ottevanger, P. B., Fruscio, R., Dahl Steffensen, K., Kolawa, W., Gziri, M. M., Han, S. N., Van Calsteren, K., Van den Heuvel, F., De Vleeschouwer, S., Clement, P. M., Menten, J., Amant, F. & ESGO 'Cancer in Pregnancy' Task Force, maj 2014, I : European Journal of Cancer. 50, 8, s. 1462-71 10 s.

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression

Steffensen, K. D., Smoter, M., Waldstrøm, M., Grala, B., Bodnar, L., Stec, R., Szczylik, C. & Jakobsen, A., maj 2014, I : International Journal of Oncology. 44, 5, s. 1736-44 9 s.

Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting

Amant, F., Halaska, M. J., Fumagalli, M., Dahl Steffensen, K., Lok, C., Van Calsteren, K., Han, S. N., Mir, O., Fruscio, R., Uzan, C., Maxwell, C., Dekrem, J., Strauven, G., Mhallem Gziri, M., Kesic, V., Berveiller, P., van den Heuvel, F., Ottevanger, P. B., Vergote, I., Lishner, M. & 3 flere, Morice, P., Nulman, I. & ESGO 'Cancer in Pregnancy' Task Force, mar. 2014, I : International Journal of Gynecological Cancer. 24, 3, s. 394-403

The need for more workshops in laparoscopic surgery and surgical anatomy for European gynaecological oncology trainees: a survey by the European Network of Young Gynaecological Oncologists

Manchanda, R., Halaska, M. J., Piek, J. M., Grabowski, J. P., Haidopoulos, D., Zapardiel, I., Gultekin, M., Vranes, B., Dallaku, K., Bossart, M., European Network of Young Gynecological Oncologists (ENYGO) & Dahl Steffensen, K., jul. 2013, I : International Journal of Gynecological Cancer. 23, 6, s. 1127-32

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer

Bechmann, T., Andersen, R. F., Pallisgaard, N., Madsen, J. S., Maae, E., Jakobsen, E. H., Bak Jylling, A. M., Steffensen, K. D. & Jakobsen, A., jun. 2013, I : Journal of Cancer Research and Clinical Oncology. Supplement. 139, 6, s. 995-1003 9 s.

Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy

Bechmann, T., Olsen, D. A., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Jylling, A. M. B., Steffensen, K. D. & Jakobsen, A., apr. 2013, I : Current Oncology Reports (Online). 29, 4, s. 1475-82 8 s.

Cancer in pregnancy: a survey of current clinical practice

Han, S. N., Kesic, V. I., Van Calsteren, K., Petkovic, S., Amant, F., ESGO 'Cancer in Pregnancy' Task Force & Dahl Steffensen, K., 2013, I : European Journal of Obstetrics & Gynecology and Reproductive Biology. 167, 1, s. 18-23

Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study

Steffensen, K. D., Waldstrøm, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2013, I : International Journal of Gynecological Cancer. 23, 1, s. 73-80

Predicting brain metastases of breast cancer based on serum S100B and serum HER2

Bechmann, T., Madsen, J. S., Brandslund, I., Lund, E. D., Ormstrup, T., Jakobsen, E. H., Jylling, A. M. B., Steffensen, K. D. & Jakobsen, A., 2013, I : Oncology Letters. 6, 5, s. 1265-1270

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)

You, B., Colombari, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. D., Reinthaller, A., Pujade-Lauraine, E. & Oza, A., 2013, I : Gynecologic Oncology. 130, 2, s. 289-94

Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2012, I : Pathology Research International. 2012, s. 851432 8 s.

Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M., Andersen, R. F., Søgaard, C., Brandslund, I. & Jakobsen, A., 2012, I : Clinical Ovarian and Other Gynecologic Cancer. 5, 1, s. 10-16

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Maae, E., Olsen, D. A., Steffensen, K. D., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., 2012, I : Breast Cancer Research and Treatment. 133, 1, s. 257-265

Prognostic Impact of VEGFA Germline Polymorphisms in Patients with HER2-positive Primary Breast Cancer

Maae, E., Andersen, R. F., Dahl Steffensen, K., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., 2012, I : Anticancer Research. 32, 9, s. 3619-3627

Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Smerdel, M., Adimi, P., Brandslund, I. & Jakobsen, A., 2012, I : Journal of Ovarian Research. 5, 1, s. 23

Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors

Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Søgaard, C., Brandslund, I. & Jakobsen, A., 2012, I : Anticancer Research. 32, 9, s. 3817-3825

The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients

Steffensen, K. D., Waldstrøm, M., Brandslund, I., Petzold, M. & Jakobsen, A., 2012, I : International Journal of Gynecological Cancer. 22, 9, s. 1474-1482

Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast

Maae, E., Nielsen, M., Dahl Steffensen, K., Jakobsen, E. H., Jakobsen, A. & Sørensen, F. B., aug. 2011, I : Journal of Histochemistry and Cytochemistry. 59, 8, s. 750-760

DNA-Repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival

Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2011, I : Journal of Cancer Therapy. 2, s. 140-147 7 s.

Gynecologic oncology training systems in europe: a report from the European network of young gynaecological oncologists

Gultekin, M., Dursun, P., Vranes, B., Laky, R., Bossart, M., Grabowski, J. P., Piek, J. M. J., Manchanda, R., Grimm, C., Dallaku, K., Babloyan, S., Moisei, A., Van Gorp, T., Cadron, I., Markov, P., Micevska, A., Halaska, M., Steffensen, K. D., Gristenko, L., Nissi, R. & 20 flere, Lambaudie, E., Tsitsishvili, Z., Haidopoulos, D., Tsolakidis, D., Novak, Z., Peiretti, M., Dunenova, G., Macuks, R., Hetland, T. E., Michelsen, T. M., Martins, F. C., Achimas-Cadariu, P., Ulrikh, E. A., Uharcek, P., Malic, S., Ognjenovic, D., Zapardiel, I., Johann, S., Sukhin, V. S. & Manchanda, R., 2011, I : International Journal of Gynecological Cancer. 21, 8, s. 1500-6 7 s.

Improved classification of epithelial ovarian cancer: results of 3 danish cohorts

Steffensen, K. D., Waldstrøm, M., Grove, A., Lund, B., Pallisgård, N. & Jakobsen, A., 2011, I : International Journal of Gynecological Cancer. 21, 9, s. 1592-600 9 s.

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer

Steffensen, K. D., Alvero, A. B., Yang, Y., Waldstrøm, M., Hui, P., Holmberg, J. C., Silasi, D-A., Jakobsen, A., Rutherford, T. & Mor, G., 2011, I : Journal of Oncology. 2011, s. 620523 12 s.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients

Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 2011, I : International Journal of Gynecological Cancer. 21, 6, s. 1040-7 8 s.

The prognostic importance of EGFR and COX-2 expression in cervix cancer stages IIb-IVa

Adimi, P., Dahl Steffensen, K., Schledermann, D., Rasmussen, E. R. & Jakobsen, A., 2011, I : Journal of Cancer Therapy. 2, 1, s. 9-15

The prognostic value of Syndecan-1 in ovarian cancer patients with long-term follow-up

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2011, I : Clinical Ovarian Cancer and Other Gynecologic Malignancies. 4, 1, s. 12-18

VEGF in the development of ovarian malignancy

Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Andersen, R. F., Olsen, D. A., Brandslund, I. & Jakobsen, A., 2011, I : Clinical Ovarian Cancer and Other Gynecologic Malignancies. 4, 1, s. 19-25

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Smerdel, M. P., Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 1. aug. 2010, I : Gynecologic Oncology. 118, 2, s. 167-71 5 s.

Supraclavicular recurrence after early breast cancer: a curable condition?

Pedersen, A. N., Møller, S., Steffensen, K. D., Haahr, V., Jensen, M., Kempel, M. M., Jepsen, S. L., Madsen, E. L., Roslind, A., Sandberg, E., Schöllkopf, C., Sørensen, P. G., Windfeldt, K. M. & Andersson, M., 8. maj 2010, I : Breast Cancer Research and Treatment. 125, 7, s. 815-822

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 5. jan. 2010, I : Gynecologic Oncology. 117, 1, s. 109-116

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M., Christensen, R. K., Bartels, A., Brüner, N. & Jakobsen, A., 1. jan. 2010, I : BMC Cancer. 10, s. 185

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M. & Jakobsen, A., 1. jul. 2009, I : International Journal of Gynecological Cancer. 19, 5, s. 820-5 5 s.

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer

Smerdel, M., Waldstrøm, M., Brandslund, I., Steffensen, K. D., Andersen, R. F. & Jakobsen, A., 1. maj 2009, I : International Journal of Gynecological Cancer. 19, 4, s. 578-84 6 s.

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Alvero, A. B., Chen, R., Fu, H-H., Montagna, M., Schwartz, P. E., Rutherford, T., Silasi, D-A., Steffensen, K. D., Waldstrøm, M., Visintin, I. & Mor, G., 1. jan. 2009, I : Cell Cycle. 8, 1, s. 158-66 8 s.

Preoperative serum levels of epidermal growth factor receptor, HER2, and vascular endothelial growth factor in malignant and benign ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Knudsen, H. J., Brandslund, I. & Jakobsen, A., 1. dec. 2008, I : Clinical Ovarian and Other Gynecologic Cancer. 1, 2, s. 127-134 8 s.

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Olsen, D. A., Jeppesen, U., Knudsen, H. J., Brandslund, I. & Jakobsen, A., 1. jul. 2008, I : International Journal of Oncology. 33, 1, s. 195-204 9 s.

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors

Steffensen, K. D., Waldstrøm, M., Olsen, D. A., Corydon, T., Lorentzen, K. A., Knudsen, H. J., Jeppesen, U., Brandslund, I. & Jakobsen, A., 1. jun. 2008, I : Clinical Cancer Research. 14, 11, s. 3278-3282 4 s.

Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells

Chen, R., Alvero, A. B., Silasi, D-A., Steffensen, K. D. & Mor, G., 7. jan. 2008, I : Oncogene. 27, 2, s. 225-233 8 s.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 24. okt. 2007, I : International Journal of Gynecological Cancer.

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Jakobsen, E., Brandslund, I. & Jakobsen, A., 2007, I : International Journal of Gynecological Cancer. 17, 4, s. 798-807 9 s.

Publikationer - abstracts

Bevacizumab in heavily pre-treated ovarian cancer patients and the predictive value of serum VEGF

Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 2009, *Abstracts*. European Cancer Organization (ECCO)

Publikationer - posters

A study in optimizing follow up for postmenopausal women with breast cancer treated with adjuvant endocrine therapy

Lundgaard Riis, C., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 29. aug. 2019.

Blood natural killer cells as a new, independent prognostic factor in recurrent ovarian cancer

Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 29. aug. 2019.

HOXA9 methylation as a prognostic marker in platinum-resistant ovarian cancer

Faaborg, L., Henriksen, J. R., Andersen, R. F., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 29. aug. 2019.

Tissue immune response in ovarian cancer

Henriksen, J. R., Donskov, F., Jakobsen, A., Waldstrøm, M., Hjortkjær, M. & Dahl Steffensen, K., 1. jun. 2019.

Development of a decision aid to support ovarian cancer patient decide on CA125 biomarker monitoring

Kargo, A. S., Coulter, A., Jensen, P. T. & Dahl Steffensen, K., 12. apr. 2019.

Prognostic Impact of NK-cells, T-cells and PD-L1 in Ovarian Cancer

Henriksen, J. R., Waldstrøm, M., Donskov, F., Jakobsen, A., Hjortkjær, M. & Dahl Steffensen, K., 22. mar. 2019.

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? - A scoping review

Christensen, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 2019.

CABAZITAXEL - A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

Madsen, C. V., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 16. sep. 2018.

SHARED DECISION MAKING IN THE CARE FOR THE GYNECOLOGIC CANCER PATIENT

Mette, H., Fokdal, L. U., Ør Knudsen, A., Madsen, C. V., Jensen, P. T., Lundvall, L., Olling, K., Lemley, B., Blou, D., Hanne, B. & Dahl Steffensen, K., 15. sep. 2018.

DEVELOPMENT OF A PATIENT DECISION AID TEMPLATE FOR USE IN DIFFERENT CLINICAL SETTINGS

Olling, K., Bechmann, T., Madsen, P. H., Hugger Jakobsen, E., Hilberg, O., Coulter, A. & Dahl Steffensen, K., 30. aug. 2018.

Kan anvendelse af Patient Reported Outcome Measures (PROM) forbedre opfølgningen af ovariecancer patienter? PROMova, et nationalt projekt.

Kargo, A. S., Coulter, A., Hjøllund, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 30. aug. 2018.

Shared decision making in care for the gynecologic cancer patient

Dahl Steffensen, K., Fokdal, L. U., Ør Knudsen, A., Madsen, C. V., Jensen, P. T., Lundvall, L., Olling, K., Lemley, B., Blou, D., Hanne, B. & Mette, H., 30. aug. 2018.

Shared decision making in decision on adjuvant radiotherapy for early stage breast cancer patients

Bechmann, T., Ellegaard, M-B. B., Hugger Jakobsen, E., Offersen, B. V., Bøje, C. R., Zachariae, B. & Dahl Steffensen, K., 30. aug. 2018.

Valg eller fravalg af CA125 blodprøver ved opfølgning af patienter med ovariecancer. Udvikling af et beslutningsstøtteværktøj

Kargo, A. S., Coulter, A., Jensen, P. T. & Dahl Steffensen, K., 30. aug. 2018.

Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.

Dahl Steffensen, K., Andersen, R. F. & Jakobsen, A., 4. jun. 2018.

Optimeret opfølgning for brystkræftpatienter i sygehusregi

Christensen, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 18. jan. 2018.

Factors affecting patient decision-making on surgery for lumbar herniated disc

Brogård Andersen, S., Birkelund, R., Andersen, M. Ø., Coulter, A., Carreon, L. Y. & Dahl Steffensen, K., 2018.

Individual survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Kargo, A. S., Coulter, A., Hjøllund, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 2018.

Validation and incorporation of oncologic and relapse data from Danish National Patient Registry (NPR) in the Danish Gynecological Cancer Database (DGCD)

Weng Ekman-Gade, A., Høgdall, C., Fagö-Olsen, C. L., Dahl Steffensen, K., Hjortkjær, M., Mejer Sørensen, S., Høgdall, E., Jochumsen, K., Antonsen, S. L., Ingerslev, K. H., Kahr, H. S. & Schnack Henriksen, T., 2018.

Is there a need for a Decision Aid in a Danish Spine Surgery Clinic or is Shared Decision Making already done?

Brogård Andersen, S., Andersen, M. Ø., Coulter, A., Carreon, L. Y. & Dahl Steffensen, K., 5. jul. 2017. 1 s.

Individual survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Kargo, A. S., Coulter, A., Hjøllund, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 2017.

Neutrophils as a prognostic factor in the systemic treatment of Ovarian Cancer

Henriksen, J. R. & Dahl Steffensen, K., 29. okt. 2016.

LBA50 - Influence of concomitant clopidogrel consumption on development of paclitaxel-associated toxicity: A pharmacoepidemiological study

K, A., Mau-Sørensen, M., Stage, T. B., Dahl Steffensen, K., Hallas, J., Brøsen, K. & Bergmann, T. K., 8. okt. 2016.

A first step in shared decision making – developing a decision aid for the choice of anal cancer radiotherapy.

Olling, K., Wee, L., Jensen, L. H. & Dahl Steffensen, K., 19. sep. 2016.

A first step in shared decision making. Developing a decision aid for the choice of anal cancer radiotherapy

Olling, K., Wee, L., Jensen, L. H. & Dahl Steffensen, K., 19. sep. 2016.

Veliparib monotherapy to patients with BRCA germline mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study

Dahl Steffensen, K., Adimi, P. & Møller Jakobsen, A. K., 6. jun. 2016.

Forsøgs- eller standard behandling?

Gregersen, T. A., Ammentorp, J., Birkelund, R., Dahl Steffensen, K. & Wolderslund, M., 2016.

Prognosis of Patients with cervical cancer diagnosed during pregnancy

Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Skultety, J., Giuliani, D., Mophon, A., Rouzier, R., Witteveen, P. O., Locatelli, A., Rob, L. & Amant, F., 2014.

The prognostic value of BRCA1 and PARP expression in epithelial ovarian carcinoma – immunohistochemical detection

Hjortkjær, M., Waldstrøm, M., Kanstrup, H., Søgaard-Andersen, E., Jakobsen, A. & Dahl Steffensen, K., 2014.

The clinical outcome in breast cancer patients with HER2 status determined by a quantitative ELISA technique

Bechmann, T., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Olsen, D. A., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 5. maj 2012.

Quantitative tissue HER2 protein concentration does not expand the group of patients eligible for adjuvant HER2-targeted therapy

Bechmann, T., Olsen, D. A., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 20. apr. 2012.

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Maae, E., Olsen, D. A., Dahl Steffensen, K., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., apr. 2012.

Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast

Maae, E., Nielsen, M., Dahl Steffensen, K., Jakobsen, E. H., Jakobsen, A. & Sørensen, F. B., mar. 2012.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study

Dahl Steffensen, K., Waldstrøm, M., Pallisgaard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2012.

The prognostic and predictive value of combined HE4 and CA125 in ovarian cancer patients

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Petzold, M. & Jakobsen, A., 2012.

The clinical significance of quantitative HER2 determination in breast cancer

Bechmann, T., Jakobsen, E. H., Madsen, J. S., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 10. mar. 2011.

Prognostic Impact of Prechemotherapy Human Epididymis Protein (HE4) and Cancer Antigen 125 (CA125) Levels in Ovarian Cancer Patients

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 6. mar. 2011.

Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.

You, B., Colombaro, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Fossati, R., Emons, G., Rehman, K. L., Petru, E., GebSKI, V., Burges, A., Tubiana-Matthieu, N., Hansen, M., Vasey, P. A., Denison, U., De Bruyne, P. & Oza, A. M., 2011.

Clinical aspects of vascular endothelial growth factor in breast cancer -Preliminary results of vascular endothelial growth factor single nucleotide polymorphisms analysis

Maae, E., Hugger Rasmussen, E., Dahl Steffensen, K., Sørensen, F. B., Brandslund, I. & Jakobsen, A., 2010.

Clinical aspects of vascular endothelial growth factor in breast cancer -Preliminary results of vascular endothelial growth factor single nucleotide polymorphisms analysis

Maae, E., Hugger Rasmussen, E., Dahl Steffensen, K., Sørensen, F. B., Brandslund, I. & Jakobsen, A., 2010.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, non-randomized, multicenter, phase II trial

Dahl Steffensen, K., Waldstrøm, M., Lund, B., Bergfeldt, K., Kjeldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2010.

Association of ERCC1 protein expression to platinum resistance in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2009.

The predictive value of CD44, Myd88 and ERCC1 to the effect of chemotherapy in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Silasi, D. & Jakobsen, A., 2009.

Absence of mutant epidermal growth factor receptor (EGFRVIII) in normal, benign, borderline and malignant ovarian tissue

Dahl Steffensen, K., Waldstrøm, M., Olsen, D. A., Corydon, T., Knudsen, H. J., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2008.

Multiplex serum tumor markers for the prediction of early relapse in ovarian cancer patients

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Brandslund, I. & Jakobsen, A., 2008.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2008.

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Andersen, R.F., Olsen, D.A., Jeppesen, U., Knudsen, H.J., Brandslund, I. & Jakobsen, A., 2008.

The predictive value of CD44, Myd88 and ERCC1 to the effect of chemotherapy in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Silasi, D., Jakobsen, A. & Mor, G., 2008.

The prognostic importance of EGFR and COX-2 expression in advanced cervix cancer

Adimi, P., Schledermann, D., Dahl Steffensen, K. & Jakobsen, A., 2008.

Comparison of immunohistochemistry and fluorescence in situ hybridization for the evaluation of Her-2 expression and prognostic value in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Jakobsen, E., Brandslund, I. & Jakobsen, A., 2007.

COX2 expression and relation to long term survival in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

COX2 expression and relation to long-term survival in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

Kvalifikationer

PhD, PhD, Syddansk Universitet
2005 → 2008

Cand Med, Aarhus Universitet
jan. 1992 → jan. 1999

Aktiviteter

Gæsteophold i udlandet